<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04812067</url>
  </required_header>
  <id_info>
    <org_study_id>TTHX-901</org_study_id>
    <nct_id>NCT04812067</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Trial of TTHX1114 in People With CED</brief_title>
  <acronym>OPTIC</acronym>
  <official_title>A Phase 2 Clinical Trial to Assess the Safety and Observe the Potential Benefit of TTHX1114 Delivered Via Intra-Cameral (IC) Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trefoil Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trefoil Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Expanded access, open label study at a single dose level in patients with CED that in the&#xD;
      opinion of the investigators might benefit from TTHX1114&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 16, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Specular Microscopy</measure>
    <time_frame>Day 28</time_frame>
    <description>Corneal Endothelial Cell Density</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pachymetry</measure>
    <time_frame>Day 28</time_frame>
    <description>Central Corneal Thickness</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Corneal Endothelial Dystrophy</condition>
  <arm_group>
    <arm_group_label>TTHX1114 weekly x 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTHX1114 via IC injection weekly x 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTHX1114</intervention_name>
    <description>engineered FGF-1</description>
    <arm_group_label>TTHX1114 weekly x 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, 18 years of age or older&#xD;
&#xD;
          -  Subjects who are women of childbearing potential (WOCBP) must be using an acceptable&#xD;
             method of birth control (See Section 6.4.3)&#xD;
&#xD;
          -  Proposed Study Eye that has been diagnosed with an ocular condition that, in the&#xD;
             opinion of the Investigator, could possibly benefit from TTHX1114 administration, and&#xD;
             has a measurable efficacy endpoint&#xD;
&#xD;
          -  Fellow Eye with 20/100 BCVA or better&#xD;
&#xD;
          -  No concurrent ocular or medical condition that would impair the assessment of safety&#xD;
             and efficacy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to TTHX1114&#xD;
&#xD;
          -  Intolerance, hypersensitivity, or significant allergy to any drug compound, food, or&#xD;
             other substance (Note: This includes all components and excipients of the study drug)&#xD;
&#xD;
          -  Current or recent (e.g., the 28 days prior to Study Day 0) participation in any other,&#xD;
             interventional clinical research study&#xD;
&#xD;
          -  History of:&#xD;
&#xD;
               -  Ocular cancer (including melanoma)&#xD;
&#xD;
               -  Herpetic keratitis&#xD;
&#xD;
               -  Documented and repeated elevated IOP in either eye&#xD;
&#xD;
               -  Posterior Polymorphous Corneal Dystrophy (PPCD; aka Schlichting dystrophy)&#xD;
&#xD;
               -  Uveitis&#xD;
&#xD;
          -  Use of any concomitant medications that may interfere with the assessment of safety&#xD;
             and efficacy&#xD;
&#xD;
          -  Any other reason (e.g., serious systemic disease or uncontrolled medical condition)&#xD;
             that, in the opinion of the Investigator could increase the subject's risk, interfere&#xD;
             with the interpretation of the study results, or affect the subject's ability to&#xD;
             provide informed consent or comply with the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Tremblay</last_name>
    <phone>4153053491</phone>
    <email>ttremblay@trefoiltherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Trefoil Study Site 124</name>
      <address>
        <city>Atlanta</city>
        <state>California</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Tremblay</last_name>
      <phone>415-305-3491</phone>
      <email>ttremblay@trefoiltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trefoil Study Site 115</name>
      <address>
        <city>Washington</city>
        <state>California</state>
        <zip>30090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Tremblay</last_name>
      <phone>415-305-3491</phone>
      <email>ttremblay@trefoiltherapeutics.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

